On the other hand, the use of metformin (an insulin sensitizer), reduces it, whereas use of sulfonylureas (insulin secretagogues) appears to increase the risk for cancer in individuals with type 2 diabetes [28]. This evidence concerns the gene INS and type 2 diabetes mellitus.